AmideBio signs partnership with CU

BOULDER – AmideBio LLC signed a research agreement with the University of Colorado at Boulder to help discover potential treatments for Alzheimer’s disease.

Working with molecular, cellular and developmental biology associate professor Michael Stowell, Boulder-based AmideBio will use a screening process to find compounds that influence the interaction between two proteins thought to be involved in Alzheimer’s disease.

AmideBio will be able to option newly discovered compounds through the collaboration. Those new compounds will hopefully be used in treating Alzheimer’s.

SPONSORED CONTENT

Select your Republic Services residential cart now!

In preparation for Republic Services becoming the primary provider of residential recycling, yard trimmings, and trash, residents should now select the best cart size and service schedule for their household needs.

“AmideBio’s commitment to our research will help to accelerate the discovery of potential therapeutics for Alzheimer’s by providing both financial support and the large quantities of amyloid peptides needed for screening,” Stowell said in a statement.

In January, the Boulder company licensed technology to develop, manufacture and commercialize peptides using a manufacturing process developed by Stowell.

And in February, the company, which was co-founded by Misha Plam who previously led Bioptix Diagnostics Inc., announced it raised $274,997 in a seed round.